CORREVIO (UK) LTD.

06481819
Active London

Other human health activities

0 employees website.com
Other human health activities
C

CORREVIO (UK) LTD.

06481819

Other human health activities

Founded 23 Jan 2008 Active London, United Kingdom 0 employees website.com
Other human health activities

Previous Company Names

IROKO CARDIO (UK) LTD. 23 Jan 2008 — 15 Jan 2013
Accounts Submitted 30 Sept 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 5 Mar 2026 Next due 6 Feb 2027 7 months remaining
Net assets £-267K £10K 2024 year on year
Total assets £2K £57K 2024 year on year
Total Liabilities £268K £67K 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

Dashwood House 69 Old Broad Street London EC2M 1QS United Kingdom

Full company profile for CORREVIO (UK) LTD. (06481819), an active company based in London, United Kingdom. Incorporated 23 Jan 2008. Other human health activities. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2014–2024)

Cash in Bank

N/A

Net Assets

-£266.60k

Increased by £10.25k (+4%)

Total Liabilities

£268.30k

Decreased by £67.34k (-20%)

Turnover

N/A

Employees

N/A

Debt Ratio

15782%

Increased by 15211 (+2664%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Mercury Pharma Group Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 3 Ceased
Active
Notified 1 Jun 2021
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

The Blackstone Group Inc.

Ceased 1 Jun 2021

Ceased

Correvio Pharma Corp.

Ceased 27 May 2020

Ceased

Cardiome Pharma Corp.

Ceased 15 May 2018

Ceased

Group Structure

Group Structure

CORREVIO (UK) LTD. Current Company

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
5 Mar 2026Confirmation StatementConfirmation statement made on 23 Jan 2026 with no updates
30 Sept 2025AccountsAnnual accounts made up to 31 Dec 2024
20 Feb 2025OfficersAppointment of Mr. Melvin Jeremy Ferry as director on 6 Feb 2025
19 Feb 2025OfficersTermination of Vikram Laxman Kamath as director on 6 Feb 2025
5 Feb 2025Confirmation StatementConfirmation statement made on 23 Jan 2025 with no updates
5 Mar 2026 Confirmation Statement

Confirmation statement made on 23 Jan 2026 with no updates

30 Sept 2025 Accounts

Annual accounts made up to 31 Dec 2024

20 Feb 2025 Officers

Appointment of Mr. Melvin Jeremy Ferry as director on 6 Feb 2025

19 Feb 2025 Officers

Termination of Vikram Laxman Kamath as director on 6 Feb 2025

5 Feb 2025 Confirmation Statement

Confirmation statement made on 23 Jan 2025 with no updates

Recent Activity

Latest Activity

Confirmation statement made on 23 Jan 2026 with no updates

3 months ago on 5 Mar 2026

Annual accounts made up to 31 Dec 2024

8 months ago on 30 Sept 2025

Appointment of Mr. Melvin Jeremy Ferry as director on 6 Feb 2025

1 years ago on 20 Feb 2025

Termination of Vikram Laxman Kamath as director on 6 Feb 2025

1 years ago on 19 Feb 2025

Confirmation statement made on 23 Jan 2025 with no updates

1 years ago on 5 Feb 2025